The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On April 17, Moderna announced an 83% overall response rate for mRNA-4359 in combination with pembrolizumab. The U.S. FDA granted Fast Track designation for this combination therapy. The study also showed a 92% disease control rate among 12 participants.